News | March 17, 2024
Sumitomo Pharma announces availability of ORGOVYX in Canada
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
_256_384.png){kind=logo}
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
Subscribe To Our Newsletter & Stay Updated
